As ovulation approaches, estrogen peaks
Oral GLP-1 RA in Development The success of orally administered semaglutide in clinical trials has led to the development of other oral formulations
Seek specialty care when appropriate: Dermatologists and obesity medicine physicians are trained to individualize treatment safely
Trial design: 751 adults with obesity (BMI 30, or 27 with at least one comorbidity) No type 2 diabetes 72-week follow-up Tirzepatide 10mg or 15mg vs Semaglutide 2.4mg Results at 72 weeks: When looking at tirzepatide weight loss results from SURMOUNT-5 alongside semaglutide weight loss results from the STEP trials, the gap is consistent and statistically significant across every subgroup sex, age, baseline BMI, and presence of metabolic comorbidities
Nonclinical Toxicology 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility In a 2-year carcinogenicity study in CD-1 mice, subcutaneous doses of 0.3, 1 and 3 mg/kg/day [9-, 33- and 113- fold the maximum recommended human dose (MRHD) of RYBELSUS 14 mg, based on AUC] were administered to the males, and 0.1, 0.3 and 1 mg/kg/day (3-, 9- and 33-fold MRHD) were administered to the females
